Sequencing

Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031

Retrieved on: 
Friday, March 1, 2024
MRI, Incidence, Breast cancer, Sequencing, Comprehensive, Traction, Hospital, Strategic planning, Growth, Implementation, Massive parallel sequencing, NGS, Lung, Patient, Optimism, Diagnosis, PCR, IVD, Cancer, Medical imaging

The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.

Key Points: 
  • The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.
  • At what rate is the demand for cancer diagnostic products in Europe projected to grow for the next 5-7 years?
  • Which countries are expected to offer significant growth opportunities for the vendors operating in the Europe cancer diagnostics market?
  • What recent developments have taken place in the Europe cancer diagnostics market, and how these strategic developments are creating an impact in this market?

Global Genomics Market Report 2023: Sector is Expected to Reach $411.35 Billion by 2030 at a CAGR of 19.4% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 12, 2023
Biotechnology, Health, Genetics, Science, Research, Molecular biology, Co-production (public services), Metagenomics, Sanger, GSA, Academic institution, Budapest Metropolitan University, Genomics, Hospital, Agriculture, Economy, NGS, Medication, Cancer, Union budget of India, RNA, MEA, Medicine, Brain, Thermo Fisher Scientific, USD, Government, Ancestry.com, TGS, Incidence, 2021 Union budget of India, FDI, Ministry of Agriculture, Animal Industry and Fisheries (Uganda), Application, Drug discovery, Plant growth analysis, Scania OmniExpress, Growth, Diagnosis, Massive parallel sequencing, Safety, PCR, Genome, Antibiotics, Vaccine, Purification, Illumina, Sequencing

The global genomics market size was valued at USD 27.81 billion in 2021 and is poised to grow from USD 33.25 billion in 2022 to USD 411.35 billion by 2030, growing at a CAGR of 19.4% in the forecast period (2023-2030).

Key Points: 
  • The global genomics market size was valued at USD 27.81 billion in 2021 and is poised to grow from USD 33.25 billion in 2022 to USD 411.35 billion by 2030, growing at a CAGR of 19.4% in the forecast period (2023-2030).
  • Government funding for genomics efforts has increased as a result of the rising incidence of cancer worldwide.
  • Global Genomics Market is segmented based on Deliverables, Technology, End Use, application, and Region.
  • The growth of Next-Generation Sequencing (NGS), which is increasingly being employed in cancer research, is driving the global genomics market.

Molecular Diagnostics Market to be Worth $31.9 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 5, 2023
Xpert, POC, Prevalence, NGS, COVID-19, Centrifugal micro-fluidic biochip, Infection, DSM-IV codes, USD, Microfluidics, Incidence, Acquisition, Miniaturization, Tuberculosis, Application, SAN, Roche, Cepheid variable, Cepheid (company), OTC, Diagnosis, Growth, Fungal infection, Power-on self-test, Cobas, PCR, Bloodstream infections, TMA, Pharmaceutical industry, Vaccine, Sequencing

The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.

Key Points: 
  • The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.
  • Read 270-page market research report, " Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Sequencing, INAAT, TMA), By Application, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.
  • Such advances are anticipated to drive the global molecular diagnostics market.

Molecular Diagnostics Market to be Worth $31.9 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 5, 2023
Xpert, POC, Prevalence, NGS, COVID-19, Centrifugal micro-fluidic biochip, Infection, DSM-IV codes, USD, Microfluidics, Incidence, Acquisition, Miniaturization, Tuberculosis, Application, SAN, Roche, Cepheid variable, Cepheid (company), OTC, Diagnosis, Growth, Fungal infection, Power-on self-test, Cobas, PCR, Bloodstream infections, TMA, Pharmaceutical industry, Vaccine, Sequencing

The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.

Key Points: 
  • The contraction in the market will be due to the decline in demand for molecular testing for COVID-19.
  • Read 270-page market research report, " Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Sequencing, INAAT, TMA), By Application, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results.
  • Such advances are anticipated to drive the global molecular diagnostics market.

Global Synthetic Biology Market Report 2023: Sector is Expected to Reach $55.37 Billion by 2030 at a CAGR of 18.97% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 2, 2023
Health, Biotechnology, DNA, Enzyme, Tool, Biosecurity, Health care, Measurement, Nanotechnology, MEA, Medicine, Oligonucleotide, Research, USD, Xeno nucleic acid, Chemistry, Synthetic biology, Application, Acid, Engineering, Plant growth analysis, European, Board for International Food and Agricultural Development, Biology, Growth, Environment, Bacteria, R, Core product, Genome, Synthetic, Food, Fine chemical, Agriculture, Microfluidics, EU, Others, Sequencing

The global Synthetic Biology market is a rapidly growing field that combines principles of engineering, biology, and chemistry to create new biological systems or modify existing ones.

Key Points: 
  • The global Synthetic Biology market is a rapidly growing field that combines principles of engineering, biology, and chemistry to create new biological systems or modify existing ones.
  • The market includes a variety of products and applications such as gene editing tools, DNA sequencing, and synthetic cells.
  • The growing demand for personalized medicine and sustainable solutions is expected to drive the market growth in the coming years.
  • The global synthetic biology market is segmented based on Product, Applications, Tool, Technology, and Region.

Global Short-read Sequencing Market 2023 - 2030: Rising Adoption of Short-read Sequencing for Personalized Medicine and Companion Diagnostics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Genetics, Health, Amgen, Workflow, COVID-19, Infection, Research, Noninvasive prenatal testing, USD, Government, Patient, Application, Bangalore, Illumina, Inc., Indian Institute of Science, Viral, Sequencing, Vaccine, Fine chemical, Video game

The global short-read sequencing market size is expected to reach USD 18.67 billion by 2030, expanding at 18.46% CAGR from 2023 to 2030.

Key Points: 
  • The global short-read sequencing market size is expected to reach USD 18.67 billion by 2030, expanding at 18.46% CAGR from 2023 to 2030.
  • The rising demand for personalized medicine and companion diagnostics is anticipated to drive the demand for short-read technologies.
  • In addition, initiatives taken by key players to enhance their market presence are expected to boost revenue generation opportunities in the short-read sequencing industry.
  • Furthermore, a rise in the adoption of sequencing platforms for genomic research purposes is expected to have a positive impact on the overall market growth.

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

Retrieved on: 
Monday, March 20, 2023
Columbia University, Medical genetics, DNA, United Nations Interpretation Service, Pediatrics, Life, GeneDx, Genomics, NICU, G6PD, Infection, The Next Four Years, Rare, Genetics, Glucose-6-phosphate dehydrogenase deficiency, Genetic disorder, Patient, Risk, WGS, Genetic testing, Diagnosis, Sequencing, Health, Gene, Bilirubin, DSM-IV codes, Antibiotics, Dietary supplement, Pharmaceutical industry, Medicine

This included 15 confirmed cases with G6PD deficiency, a genetic disorder not integrated with standard newborn screening.

Key Points: 
  • This included 15 confirmed cases with G6PD deficiency, a genetic disorder not integrated with standard newborn screening.
  • Additionally, reportable sequence variants from 238 genes screened in the GUARDIAN study were included in a retrospective analysis performed by GeneDx.
  • “GUARDIAN is quickly teaching us a lot about how to implement genome sequencing in newborns,” said Paul Kruszka, M.D., Chief Medical Officer of GeneDx.
  • Further, as more patients are diagnosed with a rare disease, clinical trials can be established that help to more quickly develop therapies that can treat, or perhaps cure, rare diseases.

Illumina launches its first product enabling long- and short-read sequencing on one instrument

Retrieved on: 
Tuesday, March 14, 2023
SAN, DSM-IV codes, F1, WGS, Benchmarking, Doctor of Philosophy, Genome, Sequencing, DNA, Workflow, Research, Illumina, Inc., SBS, Wellcome Sanger Institute, Computer data storage, Book, Macrogen, Illumina

SAN DIEGO, March 14, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to order. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina Complete Long Read Prep, Human – is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. For the first time ever, it offers users access to both long- and short-read data on the same Illumina instrument. Illumina Complete Long Reads enables a simpler workflow with drastically reduced DNA input requirements compared to other long-read offerings.

Key Points: 
  • The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina Complete Long Read Prep, Human – is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.
  • For the first time ever, it offers users access to both long- and short-read data on the same Illumina instrument.
  • Illumina Complete Long Read Prep combines Illumina sequencing by synthesis (SBS) chemistry with DRAGEN secondary analysis to deliver WGS with outstanding accuracy.
  • The price of the Illumina Complete Long Read Prep, Human sequencing assay is inclusive of short- and long-read library prep, sequencing, and cloud analysis.

Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases

Retrieved on: 
Thursday, March 9, 2023
Technology, Genetics, Other Technology, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, Pharmaceutical, Health, Conjugation, Informatics, PCR, Ansa, Ansam Sawalha, Research, CRISPR, Community Access Program, Genetic engineering, DNA, AAV, Oligonucleotide, GC, Sequencing, Protein engineering, Fine chemical

Ansa Biotechnologies, Inc ., a pioneer of next-generation DNA synthesis, today announced the successful de novo synthesis of the world’s longest DNA oligonucleotide ever reported to be produced in a single synthesis.

Key Points: 
  • Ansa Biotechnologies, Inc ., a pioneer of next-generation DNA synthesis, today announced the successful de novo synthesis of the world’s longest DNA oligonucleotide ever reported to be produced in a single synthesis.
  • Today, high-throughput synthesis of oligonucleotides up to 350 bases enables genome-wide CRISPR experiments and new methods for protein engineering.
  • The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences.
  • To join the Early Access Program or learn more about Ansa Biotechnologies, please visit ansabio.com/signup .